{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:06:14Z","timestamp":1766066774376},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Investigator Initiated Studies Program of Merck&Co., Inc.","award":["34851"],"award-info":[{"award-number":["34851"]}]}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.numecd.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T06:47:11Z","timestamp":1507963631000},"page":"1123-1129","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response"],"prefix":"10.1016","volume":"27","author":[{"given":"A.","family":"Tura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.I.","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2017.10.006_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073154","article-title":"Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes","volume":"8","author":"Mari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2017.10.006_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2017.10.006_bib5","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.numecd.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/dc13-0465","article-title":"Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies","volume":"36","author":"Calanna","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2017.10.006_bib7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2017.10.006_bib8","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the addition-PRO study","volume":"64","author":"Faerch","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2017.10.006_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00125-008-0943-x","article-title":"Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes","volume":"51","author":"Hojberg","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2017.10.006_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"10.1016\/j.numecd.2017.10.006_bib11","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/diabetes.53.suppl_3.S220","article-title":"Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2017.10.006_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2017.10.006_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00125-014-3219-7","article-title":"Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic","volume":"57","author":"Tura","year":"2014","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.26.2007.S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"26","author":"Expert Committee on the D, Classification of Diabetes M","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2017.10.006_bib15","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jc.2009-0921","article-title":"Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus","volume":"94","author":"Hare","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2017.10.006_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0167-0115(84)90005-3","article-title":"The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera","volume":"9","author":"Krarup","year":"1984","journal-title":"Regul Pept"},{"key":"10.1016\/j.numecd.2017.10.006_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2017.10.006_bib18","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.S221","article-title":"Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation","volume":"51","author":"Mari","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2017.10.006_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.24.3.539","article-title":"A model-based method for assessing insulin sensitivity from the oral glucose tolerance test","volume":"24","author":"Mari","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2017.10.006_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.regpep.2004.06.020","article-title":"Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes","volume":"122","author":"Nauck","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.numecd.2017.10.006_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1463-1326.2011.01549.x","article-title":"Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity","volume":"14","author":"Knop","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2017.10.006_bib22","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2017.10.006_bib23","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/jc.2014-4009","article-title":"Beta-cell sensitivity to GLP-1 in healthy humans is variable and proportional to insulin sensitivity","volume":"100","author":"Aulinger","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2017.10.006_bib24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00125-012-2459-7","article-title":"Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes","volume":"55","author":"Jensen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2017.10.006_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/diab.29.2.140","article-title":"Inhibition of gastric inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes","volume":"29","author":"Creutzfeldt","year":"1980","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2017.10.006_bib26","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diacare.24.9.1640","article-title":"Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men","volume":"24","author":"Rask","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2017.10.006_bib27","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.numecd.2017.10.006_bib28","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475317302338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475317302338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T16:37:24Z","timestamp":1659631044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475317302338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0939475317302338"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2017.10.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}